This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_KAPOSI_SARCOMA_EXALLC for full statistics.
Kaposi sarcoma
C3_KAPOSI_SARCOMA
Kaposi's sarcoma: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
61 |
4. Check minimum number of eventsNone |
61 |
5. Include endpointsNone |
61 |
6. Filter based on genotype QC (FinnGen only) |
61 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- C45-C49
- Name in latin
- Sarcoma Kaposi
Similar endpoints
↥List of similar endpoints to
Kaposi sarcoma
based on the number of shared cases.
Similar with more cases:
- Kaposi sarcoma, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of mesothelium and soft tissue
- Malignant neoplasm of mesothelium and soft tissue, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 61 | 16 | 45 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 72.97 | 66.89 | 75.13 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 52
- Matched controls
- 520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C46.0
ICD-10 Finland
Kaposi sarcoma of skin
+∞
39.8
33
*
9140/3-C44.7
ICD-O-3
Kaposi sarcoma of skin of lower limb and hip
+∞
18.9
17
*
C46.9
ICD-10 Finland
Kaposi sarcoma, unspecified
+∞
11.9
11
*
C46.3
ICD-10 Finland
Kaposi sarcoma of lymph nodes
+∞
6.4
6
*
B23.1
ICD-10 Finland
HIV disease resulting in (persistent) generalized lymphadenopathy
+∞
6.4
6
*
C46.7
ICD-10 Finland
Kaposi sarcoma of other sites
+∞
6.4
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
8
14
6.39
3.47
3.8
1.7
—
—
—
0
0
6
12
5.41
2.46
4.3
1.5
—
—
—
0
0
34
230
2.08
2.04
12.4
6.5
9.9
11.9
umol/l
1.02
34
219
14
73
2.19
1.59
2.9
2.6
—
—
—
0
0
13
66
2.23
1.57
2.3
2.7
1.5
1.1
e6/l
—
7
39
6
21
3.05
1.54
1.7
1.3
—
—
—
0
0
13
67
2.19
1.52
3.1
3.1
1.4
0.8
e6/l
—
7
41
23
150
1.86
1.42
1.7
2.2
86.0
83.5
pmol/l
0.11
17
78
16
92
2.00
1.42
1.7
1.7
1.4
1.3
mmol/l
0.18
16
72
25
171
1.78
1.31
8.8
4.4
—
—
—
0
0
6
25
2.55
1.27
3.2
4.4
71.5
94.6
ng/l
—
6
19
18
112
1.86
1.27
4.4
3.5
361.3
4689.3
umol/l
0.50
18
95
24
165
1.75
1.23
3.8
3.5
—
—
—
0
0
7
32
2.34
1.12
5.6
4.3
0.1
0.1
e6/l
—
7
32
11
60
2.02
1.11
4.3
4.6
—
—
—
0
0
7
33
2.26
1.09
1.4
2.5
33.6
25.8
u/l
—
7
28
28
207
1.65
1.08
7.2
5.4
0.0
0.0
estimate
—
5
49
13
77
1.87
1.05
2.8
2.4
11.5
12.0
umol/l
0.06
13
67
28
211
1.60
0.98
5.2
4.3
0.0
0.0
estimate
—
6
47
12
72
1.83
0.93
2.8
2.5
2.3
2.3
g/l
0.01
12
64
8
45
1.89
0.88
2.5
1.6
—
—
—
0
0
27
206
1.56
0.87
5.1
4.2
0.0
0.0
estimate
—
6
50
6
32
1.97
0.84
5.3
4.1
1.2
2.4
mmol/l
—
6
25
43
371
1.54
0.75
25.6
18.6
76.4
73.4
ml/min/173m2
0.31
34
296
46
420
1.39
0.44
34.4
21.2
83.3
87.6
umol/l
0.54
46
420
44
400
1.36
0.43
32.4
18.6
23.9
25.5
mg/l
0.16
38
330
5
34
1.51
0.41
1.0
1.4
—
—
—
0
0
9
70
1.33
0.39
1.1
1.1
—
0.8
—
0
22
11
83
1.40
0.35
2.1
1.9
—
—
—
0
0
6
45
1.37
0.35
4.3
3.3
6.3
5.9
kpa
—
6
45
44
408
1.28
0.31
31.4
21.7
139.0
139.6
mmol/l
0.86
44
396
44
412
1.24
0.25
31.5
21.7
4.0
4.0
mmol/l
0.20
44
400
5
39
1.31
0.23
2.8
2.5
1.4
1.7
%
—
5
33
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
19
166
1.21
0.21
5.4
4.5
—
—
—
0
0
14
119
1.23
0.20
3.1
3.0
0.7
0.7
ug/l
—
9
74
7
57
1.26
0.19
1.1
1.8
—
—
—
0
0
7
59
1.21
0.19
1.4
1.8
—
—
—
0
0
23
210
1.15
0.15
2.1
2.5
—
—
—
0
0
15
132
1.18
0.15
4.3
4.5
0.0
0.0
estimate
—
5
44
15
134
1.16
0.12
1.9
2.6
52.1
55.1
u/l
0.09
15
128
28
262
1.13
0.12
4.1
3.6
15.7
15.0
pmol/l
0.60
23
225
19
174
1.13
0.11
5.9
4.3
18.0
21.1
%
—
6
76
40
384
1.12
0.10
13.6
5.2
6.1
6.1
mmol/l
0.00
35
344
15
145
1.05
0.00
2.3
2.1
150.5
288.5
u/l
0.53
15
137
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
16.7
—
0
6
0
6
0.00
0.00
0.0
7.0
—
107.1
—
0
6
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
6
60
1.00
0.00
1.8
7.8
4.8
4.9
kpa
—
6
55
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_KAPOSI_SARCOMA – Kaposi sarcoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).